in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
61<br />
NOP (ORL1) - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0358<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
ExpresS Profile<br />
High-throughput profile<br />
Diversity profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (HEK-293 cells)<br />
[ 3 H]nocicept<strong>in</strong> (0.2 nM)<br />
0.4 nM<br />
nocicept<strong>in</strong> (1 µM)<br />
nocicept<strong>in</strong> (IC 50 : 1.1 nM)<br />
Ardati, A. et al. (1997) Mol. Pharmacol., 51: 816-824.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
opioid and opioid-like ❚<br />
100<br />
50<br />
nocicept<strong>in</strong><br />
DAMGO<br />
<br />
0<br />
DPDPE<br />
U 50488<br />
-12 -11 -10 -9 -8 -7 -6 -5<br />
log [drug] (M)<br />
<strong>Cerep</strong><br />
services<br />
<br />
Receptors<br />
[GPCRs]<br />
NOP (ORL1)<br />
cellul ar<br />
Ref. 2381 Agonist effect<br />
Ref. 2382 Antagonist effect<br />
Q 3 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product cAMP<br />
Detection method HTRF<br />
Agonist effect Control nocicept<strong>in</strong> (10 nM)<br />
Reference nocicept<strong>in</strong> (EC 50 : 0.1 nM)<br />
Antagonist effect Stimulant nocicept<strong>in</strong> (1 nM)<br />
Reference UFP-101 (IC 50 : 64 nM)<br />
New, D.C. and Wong, Y.H. (2002) Neurosign., 11: 197-212.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.3%<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Ion<br />
channels<br />
Transporters<br />
NOP (ORL1)<br />
tissue<br />
Ref. 1226<br />
Q 4 weeks<br />
Source<br />
mouse vas deferens (field-stimulated)<br />
Agonist nocicept<strong>in</strong> (pD 2 = 7.9)<br />
Antagonist UFP-101<br />
Test concentrations 3 concentrations, n=2 (2 tissues)<br />
for both activities<br />
[Solvent] must be kept ≤ 0.1%<br />
Calo, G. et al. (2002) Brit. J. Pharmacol., 136: 303-311.<br />
tension (% of control)<br />
<br />
<br />
<br />
<br />
<br />
<br />
100<br />
<br />
<br />
<br />
<br />
50 <br />
<br />
0<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
log [agonist] (M)<br />
<br />
-11 -10 -9 -8 -7 -6<br />
<br />
K<strong>in</strong>ases<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
❚ Orex<strong>in</strong><br />
Other<br />
enzymes<br />
OX 1 - agonist radioligand<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Ligand<br />
[ 125 I]orex<strong>in</strong>-A (0.1 nM)<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Kd<br />
10 nM<br />
Ref. 1987<br />
Non specific SB 334867 (1 µM)<br />
Q 3 weeks<br />
Reference orex<strong>in</strong>-A (IC 50 : 0.49 nM)<br />
Included <strong>in</strong>:<br />
Organ safety profile<br />
Langmead, C.J. et al. (2004) Brit. J. Pharmacol., 141: 340-346.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Specialized<br />
cellular<br />
assays<br />
Standard<br />
profiles<br />
OX 1<br />
cellul ar<br />
Ref. 2234<br />
Ref. 2235<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product <strong>in</strong>tracellular [Ca 2+ ]<br />
Detection method fluorimetry<br />
Agonist effect Control orex<strong>in</strong>-A (10 nM)<br />
Reference orex<strong>in</strong>-A (EC 50 : 0.8 nM)<br />
Antagonist effect Stimulant orex<strong>in</strong>-A (3 nM)<br />
Reference SB 334867 (IC 50 : 210 nM)<br />
Smart, D. et al. (2001) Brit. J. Pharmacol., 132: 1179-1182.<br />
Ca 2+ mobilization (% of control)<br />
100<br />
100<br />
<br />
50<br />
50<br />
0<br />
0<br />
-9 -8 -7 -6 -8 -11 -10 -7 -6 -5<br />
log [agonist] (M)<br />
log [antagonist] (M)<br />
orex<strong>in</strong>-A<br />
SB 334867<br />
<br />
orex<strong>in</strong>-B<br />
SB 408124<br />
[Ala 11 ,D-Leu 15 ]-orex<strong>in</strong>-B<br />
<br />
[Solvent] must be kept ≤ 0.3%<br />
Test<strong>in</strong>g<br />
conditions<br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
For further details and updated <strong>in</strong>formation on assays:<br />
❚ Please go to www.cerep.com catalog onl<strong>in</strong>e or contact us at sales@cerep.com<br />
-12 -11<br />
-11 -10 -9 -8 -7 -6 -5 -4<br />
<br />
-12 -11<br />
-10 -9 -8 -7<br />
❚ Europe: +33 (0)5 49 89 30 00 – USA: +1 (425) 895 8666 – Japan: +81 (0)3 3354 4026 – Ch<strong>in</strong>a: -12 -11+86 -10 -921 -8 5132 -7 0568<br />
Assay developed <strong>in</strong> 2010 New assay conditions Human Q Standard turnaround time<br />
-10 -9 -8 -7 -6 -5<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
-11 -10<br />
-9 -8 -7 -6 -5 -4<br />
Assay list<br />
& <strong>in</strong>dex